GlaxoSmithKline PLC has decided to exercise an option giving it the right to exclusively license from Galápagos NV two compounds against immuno-inflammatory diseases. The compounds are part of an alliance dating from 2006. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
